Evidence map›Paper›PMID 33295653›Full record

ArticleTransfusion2021

Association between renal failure and red blood cell alloimmunization among newly transfused patients.

Josine A Oud, Dorothea Evers, Rutger A Middelburg, Karen M K de Vooght, Daan van de Kerkhof, Otto Visser, Nathalie C V Péquériaux, Francisca Hudig, Johanna G van der Bom, Jaap Jan Zwaginga

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Transfusion, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Red cell alloimmunization in chronic kidney disease.Asian journal of transfusion science
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Josine A OudCenter for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.ORCID 0000-0002-8985-6627
Dorothea EversDepartment of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Rutger A MiddelburgCenter for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.
Karen M K de VooghtDepartment of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Daan van de KerkhofDepartment of Clinical Chemistry and Hematology, Catharina Hospital, Eindhoven, The Netherlands.
Otto VisserDepartment of Hematology, Amsterdam University Medical Center, location VU Medical Center, Amsterdam, The Netherlands.
Nathalie C V PéquériauxDepartment of Clinical Chemistry and Hematology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
Francisca HudigLabWest, Haga Teaching Hospital, The Hague, The Netherlands.
Johanna G van der BomCenter for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.
Jaap Jan ZwagingaCenter for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.
Leiden University Medical Center · NLRadboud University Nijmegen · NLAmsterdam University Medical Centers · NLHaga Hospital · NLJeroen Bosch Ziekenhuis · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal failure and renal replacement therapy (RRT) affect the immune system and could therefore modulate red blood cell (RBC) alloimmunization after transfusion. STUDY DESIGN AND

methodsWe performed a nationwide multicenter case-control study within a source population of newly transfused patients between 2005 and 2015. Using conditional multivariate logistic regression, we compared first-time transfusion-induced RBC alloantibody formers (N = 505) with two nonalloimmunized recipients with similar transfusion burden (N = 1010).

resultsRenal failure was observed in 17% of the control and 13% of the case patients. A total of 41% of the control patients and 34% of case patients underwent acute RRT. Renal failure without RRT was associated with lower alloimmunization risks after blood transfusion (moderate renal failure: adjusted relative rate [RR], 0.82 [95% confidence interval (CI), 0.67-1.01]); severe renal failure, adjusted RR, 0.76 [95% CI, 0.55-1.05]). With severe renal failure patients mainly receiving RRT, the lowest alloimmunization risk was found in particularly these patients [adjusted RR 0.48 (95% CI 0.39-0.58)]. This was similar for patients receiving RRT for acute or chronic renal failure (adjusted RR, 0.59 [95% CI, 0.46-0.75]); and adjusted RR, 0.62 [95% CI 0.45-0.88], respectively).

conclusionThese findings are indicative of a weakened humoral response in acute as well as chronic renal failure, which appeared to be most pronounced when treated with RRT. Future research should focus on how renal failure and RRT mechanistically modulate RBC alloimmunization.

Indexed as

AgedBlood TransfusionCase-Control StudiesCorrelation of DataErythrocytesErythrocyte TransfusionFemaleHumansKidney Failure, ChronicLogistic ModelsMaleMiddle AgedRenal InsufficiencyRenal Insufficiency, ChronicRenal Replacement TherapyRisk Factorsblood transfusiondialysisred blood cell alloimmunizationrenal failurerenal replacement therapy

Identifiers

PMID33295653
PMCPMC7839777
OpenAlexW3112599097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.